Skip to content
DataLookout
Menu

NCT04516681

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Minor Interventions: Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug) to Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOX Protocol (Drug)v3
  3. Notable Primary and study completion dates pushed to Dec 1, 2025
    • Start date: Sep 1, 2020 to Dec 1, 2024
    • Interventions: Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug) to Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug)
    • Study title expanded, about 3 words
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate
Timeframe: up to 5 years

Secondary (2)

Progression Free Survival
Overall Survival

Arms and interventions

Combined Ascorbic Acid with Adebrelimab and chemotherapy groupExperimental

Ascorbic Acid with Adebrelimab and FOLFOX ± bevacizumab. Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks

Chemotherapy alone groupActive comparator

standard FOLFOX treatment

Drugs: Ascorbic acid, FOLFOX Protocol, Adebrelimab

Sites

1 site in 1 country

  • Fudan university shanghai cancer centerShanhai, Shanghai Municipality, China